×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
VRCA – verrica pharmaceuticals inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
VRCA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/18
08:05 am
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
Low
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $17.00 price target on the stock.
12/18
08:03 am
vrca
Verrica Pharmaceuticals (NASDAQ:VRCA) was given a new $17.00 price target on by analysts at Loop Capital.
Low
Report
Verrica Pharmaceuticals (NASDAQ:VRCA) was given a new $17.00 price target on by analysts at Loop Capital.
11/24
08:00 am
vrca
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
Low
Report
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
11/14
05:27 pm
vrca
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Medium
Report
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/14
04:54 pm
vrca
Verrica Pharmaceuticals Non-GAAP EPS of $0.13, revenue of $14.3M [Seeking Alpha]
Medium
Report
Verrica Pharmaceuticals Non-GAAP EPS of $0.13, revenue of $14.3M [Seeking Alpha]
11/14
04:05 pm
vrca
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
Medium
Report
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
11/10
08:40 am
vrca
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting [Yahoo! Finance]
Medium
Report
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting [Yahoo! Finance]
11/10
08:00 am
vrca
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
Medium
Report
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
Date
Time
Symbol
Company Name
Action
%Chg
11/14/2025
04:05 pm
vrca
verrica pharmaceuticals inc.
BEAT
Report
-5.1%
verrica pharmaceuticals inc.
8/12/2025
04:01 pm
vrca
verrica pharmaceuticals inc.
BEAT
Report
-3.4%
verrica pharmaceuticals inc.
5/13/2025
04:05 pm
vrca
verrica pharmaceuticals inc.
BEAT
Report
-2.7%
verrica pharmaceuticals inc.
3/11/2025
04:05 pm
vrca
verrica pharmaceuticals inc.
BEAT
Report
-7.6%
verrica pharmaceuticals inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/15
04:16 pm
vrca
Form S-3 Verrica Pharmaceuticals
High
Report
Form S-3 Verrica Pharmaceuticals
12/3
03:20 pm
vrca
Form SCHEDULE 13G Verrica Pharmaceuticals Filed by: Affinity Asset Advisors, LLC
Low
Report
Form SCHEDULE 13G Verrica Pharmaceuticals Filed by: Affinity Asset Advisors, LLC
11/28
05:11 pm
vrca
Form SCHEDULE 13D/A Verrica Pharmaceuticals Filed by: Manning Paul B
High
Report
Form SCHEDULE 13D/A Verrica Pharmaceuticals Filed by: Manning Paul B
11/25
07:00 pm
vrca
Form 4 Verrica Pharmaceuticals For: Nov 25 Filed by: Manning Paul B
High
Report
Form 4 Verrica Pharmaceuticals For: Nov 25 Filed by: Manning Paul B
11/25
07:00 pm
vrca
Form 4 Verrica Pharmaceuticals For: Nov 25 Filed by: Rieger Jayson
High
Report
Form 4 Verrica Pharmaceuticals For: Nov 25 Filed by: Rieger Jayson
11/25
07:00 pm
vrca
Form 4 Verrica Pharmaceuticals For: Nov 25 Filed by: Rosenberg Noah L.
High
Report
Form 4 Verrica Pharmaceuticals For: Nov 25 Filed by: Rosenberg Noah L.
11/25
07:00 pm
vrca
Form 4 Verrica Pharmaceuticals For: Nov 25 Filed by: Kirby John J.
High
Report
Form 4 Verrica Pharmaceuticals For: Nov 25 Filed by: Kirby John J.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) is now covered by analysts at Needham & Company LLC. They set a "buy" rating on the stock.
33.8%
3/17 Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 22.8%
3/19 Verrica Pharmaceuticals Inc (NASDAQ: VRCA) had its "buy" rating re-affirmed by analysts at HC Wainwright. 22.5%
6/27 Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial of VP-102 for the Treatment of External Genital Warts 20.0%
6/6 Form 4 Verrica Pharmaceuticals For: Jun 04 Filed by: Davidson Matt 12.6%
9/9 Form 4 Verrica Pharmaceuticals For: Sep 05 Filed by: Davidson Matt 12.5%
3/13 Q4/2019 12/31/2019 EPS -0.310 ZacksConsensus -0.300 ActVsEst (0.010) - Miss 12.2%
6/12 Form 8-K Verrica Pharmaceuticals For: Jun 12 10.5%
7/8 Form 4 Verrica Pharmaceuticals For: Jul 03 Filed by: Davidson Matt 9.5%
11/25 Verrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference 8.5%
3/17 Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 22.8%
3/19 Verrica Pharmaceuticals Inc (NASDAQ: VRCA) had its "buy" rating re-affirmed by analysts at HC Wainwright. 22.5%
6/27 Verrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial of VP-102 for the Treatment of External Genital Warts 20.0%
6/6 Form 4 Verrica Pharmaceuticals For: Jun 04 Filed by: Davidson Matt 12.6%
9/9 Form 4 Verrica Pharmaceuticals For: Sep 05 Filed by: Davidson Matt 12.5%
3/13 Q4/2019 12/31/2019 EPS -0.310 ZacksConsensus -0.300 ActVsEst (0.010) - Miss 12.2%
6/12 Form 8-K Verrica Pharmaceuticals For: Jun 12 10.5%
7/8 Form 4 Verrica Pharmaceuticals For: Jul 03 Filed by: Davidson Matt 9.5%
11/25 Verrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference 8.5%
TOP News Decliners
3/13
Form 8-K Verrica Pharmaceuticals For: Mar 10
-21.6%
10/18 Form 8-K Verrica Pharmaceuticals For: Oct 18 -12.3%
6/27 Form 8-K Verrica Pharmaceuticals For: Jun 26 -11.2%
8/1 Form 4 Verrica Pharmaceuticals For: Jul 30 Filed by: Davidson Matt -10.0%
11/27 Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum -9.8%
10/21 Form 4 Verrica Pharmaceuticals For: Oct 18 Filed by: DAVIS A BRIAN -7.3%
7/1 Form 8-K Verrica Pharmaceuticals For: Jul 01 -5.6%
8/9 Form 4 Verrica Pharmaceuticals For: Aug 07 Filed by: Davidson Matt -5.3%
7/29 Form 4 Verrica Pharmaceuticals For: Jul 25 Filed by: Davidson Matt -5.1%
3/27 Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.4%
10/18 Form 8-K Verrica Pharmaceuticals For: Oct 18 -12.3%
6/27 Form 8-K Verrica Pharmaceuticals For: Jun 26 -11.2%
8/1 Form 4 Verrica Pharmaceuticals For: Jul 30 Filed by: Davidson Matt -10.0%
11/27 Verrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum -9.8%
10/21 Form 4 Verrica Pharmaceuticals For: Oct 18 Filed by: DAVIS A BRIAN -7.3%
7/1 Form 8-K Verrica Pharmaceuticals For: Jul 01 -5.6%
8/9 Form 4 Verrica Pharmaceuticals For: Aug 07 Filed by: Davidson Matt -5.3%
7/29 Form 4 Verrica Pharmaceuticals For: Jul 25 Filed by: Davidson Matt -5.1%
3/27 Verrica Pharmaceuticals Inc (NASDAQ: VRCA) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: